EP3397269A4 - Stable glucagon peptide formulations - Google Patents
Stable glucagon peptide formulations Download PDFInfo
- Publication number
- EP3397269A4 EP3397269A4 EP16863067.1A EP16863067A EP3397269A4 EP 3397269 A4 EP3397269 A4 EP 3397269A4 EP 16863067 A EP16863067 A EP 16863067A EP 3397269 A4 EP3397269 A4 EP 3397269A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- glucagon peptide
- peptide formulations
- stable glucagon
- stable
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060003199 Glucagon Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/930,041 US9782344B2 (en) | 2013-08-22 | 2015-11-02 | Stable glucagon peptide formulations |
PCT/US2016/060601 WO2017079611A1 (en) | 2015-11-02 | 2016-11-04 | Stable glucagon peptide formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3397269A1 EP3397269A1 (en) | 2018-11-07 |
EP3397269A4 true EP3397269A4 (en) | 2019-09-04 |
Family
ID=58662794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16863067.1A Pending EP3397269A4 (en) | 2015-11-02 | 2016-11-04 | Stable glucagon peptide formulations |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3397269A4 (en) |
WO (1) | WO2017079611A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3416618A1 (en) | 2016-02-19 | 2018-12-26 | ZP Opco, Inc. | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines |
US11660264B2 (en) | 2017-08-23 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
US11660265B2 (en) | 2018-06-28 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09241295A (en) * | 1996-03-06 | 1997-09-16 | Shiseido Co Ltd | Skin preparation for external use |
US20110097386A1 (en) * | 2009-10-22 | 2011-04-28 | Biodel, Inc. | Stabilized glucagon solutions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE221400T1 (en) | 1997-12-11 | 2002-08-15 | Alza Corp | DEVICE FOR INCREASE THE TRANSDERMAL FLOW OF ACTIVE INGREDIENTS |
IL155389A0 (en) | 2000-10-13 | 2003-11-23 | Alza Corportion | Microprotrusion member retainer for impact applicator |
IL155583A0 (en) | 2000-10-26 | 2003-11-23 | Alza Corp | Transdermal drug delivery devices having coated microprotrusions |
US6855372B2 (en) | 2001-03-16 | 2005-02-15 | Alza Corporation | Method and apparatus for coating skin piercing microprojections |
WO2007011958A2 (en) * | 2005-07-15 | 2007-01-25 | Emisphere Technologies, Inc. | Intraoral dosage forms of glucagon |
WO2011162830A2 (en) * | 2010-06-24 | 2011-12-29 | Biousian Biosystems, Inc. | Glucagon-like peptide-1 glycopeptides |
US9782344B2 (en) * | 2013-08-22 | 2017-10-10 | Zp Opco, Inc. | Stable glucagon peptide formulations |
WO2015027173A1 (en) * | 2013-08-22 | 2015-02-26 | Zp Opco, Inc. | Stable glucagon peptide formulations |
-
2016
- 2016-11-04 WO PCT/US2016/060601 patent/WO2017079611A1/en active Application Filing
- 2016-11-04 EP EP16863067.1A patent/EP3397269A4/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09241295A (en) * | 1996-03-06 | 1997-09-16 | Shiseido Co Ltd | Skin preparation for external use |
US20110097386A1 (en) * | 2009-10-22 | 2011-04-28 | Biodel, Inc. | Stabilized glucagon solutions |
Non-Patent Citations (1)
Title |
---|
See also references of WO2017079611A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017079611A1 (en) | 2017-05-11 |
EP3397269A1 (en) | 2018-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3337502A4 (en) | Stable anti-ifnar1 formulation | |
EP3270960A4 (en) | Vector formulations | |
EP3268045A4 (en) | Epinephrine formulations | |
EP3102190A4 (en) | Novel pharmaceutical formulations | |
EP3347035A4 (en) | Cartilage-homing peptides | |
PT4070788T (en) | Pharmaceutical formulations | |
HK1254343A1 (en) | Pharmaceutical formulations | |
EP3541385A4 (en) | Pharmaceutical formulations | |
EP3368012A4 (en) | Lisinopril formulations | |
EP3618840C0 (en) | Stable insulin formulations | |
EP3035952A4 (en) | Stable glucagon peptide formulations | |
EP3454847A4 (en) | Improved drug formulations | |
EP3025705B8 (en) | Stable ivabradine formulations | |
EP3402470A4 (en) | Stable pharmaceutical composition | |
AU2016218074B2 (en) | Pharmaceutical formulation | |
ZA201707094B (en) | Pharmaceutical formulations | |
EP3429581A4 (en) | Enalapril formulations | |
EP3373928A4 (en) | Novel formulations | |
EP3337463A4 (en) | Pharmaceutical formulations | |
EP3266794A4 (en) | Peptide | |
EP3397269A4 (en) | Stable glucagon peptide formulations | |
EP3383371A4 (en) | Pharmaceutical formulation | |
EP3290036A4 (en) | Stabilized pharmaceutical composition | |
EP3388089A4 (en) | Peptide composition | |
GB2541483B (en) | Antimicrobial peptide formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180601 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190807 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/19 20060101ALI20190801BHEP Ipc: A61M 37/00 20060101ALI20190801BHEP Ipc: A61K 47/26 20060101ALI20190801BHEP Ipc: A61K 47/12 20060101ALI20190801BHEP Ipc: A61K 38/26 20060101AFI20190801BHEP Ipc: A61K 47/24 20060101ALI20190801BHEP Ipc: A61K 47/18 20170101ALI20190801BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20221212 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: EMERGEX USA CORPORATION |